About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Cardiovascular Diseases group is a translational research group within the Cardiology Department of Vall d’Hebron Hospital that performs laboratory, clinical and epidemiological research. In the CIBERCV network we are within the topic of descriptor 2 “Arterial disease, thrombosis and myocardial ischemia-reperfusion injury”. Our contributions in these topics address the following lines:
In the CIBERESP network, our group is interested in the study of effectiveness/cost-effectiveness of cardiovascular interventions, health outcome research and methods in clinical research. The group has 19 principal investigators, 32 active projects and clinical trial and has been done 142 publications in 2020.
PMID: 33478914 Journal: REVISTA ESPANOLA DE CARDIOLOGIA Year: 2021 Reference: Rev Esp Cardiol (Engl Ed). 2021 Apr;74(4):290-292. doi: 10.1016/j.rec.2020.10.022. Epub 2021 Jan 19. Impact factor: 4.753 Publication type: Editorial in national publication Authors: Rodriguez-Palomares, Jose F et al. DOI: 10.1016/j.rec.2020.10.022
PMID: 33469560 Journal: Anales de pediatria Year: 2021 Reference: An Pediatr (Engl Ed). 2021 Feb;94(2):116.e1-116.e11. doi: 10.1016/j.anpede.2020.09.005. Epub 2021 Jan 14. Impact factor: 0 Publication type: Paper in international publication Authors: Garcia-Salido, Alberto, Anton, Jordi, David Martinez-Pajares, Jose, Garcia, Gemma Giralt, Cortes, Borja Gomez, Tagarro, Alfredo et al. DOI: 10.1016/j.anpede.2020.09.005
PMID: 33461928 Journal: REVISTA ESPANOLA DE CARDIOLOGIA Year: 2021 Reference: Rev Esp Cardiol. 2021 Nov;74(11):935-942. doi: 10.1016/j.rec.2020.12.003. Epub 2021 Jan 16. Impact factor: 4.753 Publication type: Paper in national publication Authors: Ferreira-Gonzalez, Ignacio, Moya-Mitjans, Angel, Miranda, Berta, Roses-Noguer, Ferran, Rivas-Gandara, Nuria, Francisco-Pascual, Jaume, Pijuan-Domenech, Antonia, Ribera-Sole, Aida, Dos-Subira, Laura, Benito, Begona et al. DOI: 10.1016/j.rec.2020.12.003
PMID: 33043545 Journal: EUROPEAN JOURNAL OF NEUROLOGY Year: 2021 Reference: Eur J Neurol. 2021 Feb;28(2):540-547. doi: 10.1111/ene.14579. Epub 2020 Nov 13. Impact factor: 6.089 Publication type: Paper in international publication Authors: Francisco-Pascual, Jaume, Bustamante, Alejandro, Penalba, Anna, Comas, Imma, Rodriguez, Maite, De Lera Alfonso, Mercedes, Arenillas, Juan F, de Torres, Reyes, Perez-Sanchez, Soledad, Cabezas, Juan Antonio et al. DOI: 10.1111/ene.14579
The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.
In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.
The Cardiovascular Diseases and Neurovascular Diseases groups at VHIR will investigate new therapeutic strategies for heart failure, nanomedicine in stroke and the prevention of cardiovascular toxicity in the case of oncological treatments.
